GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
- Proceeds to Facilitate Clinical Development of Lead Conjugate Vaccine
GlycoVaxyn, a pioneer in the development of innovative conjugated
vaccines, today announced the successful closing of a
Conjugated vaccines provide protection against a growing range of life-threatening bacterial infections. GlycoVaxyn has developed a proprietary technology that allows the engineering of a new type of conjugate vaccine, glycoconjugates. This innovation will enable GlycoVaxyn to address significant unmet medical needs in both industrialized and emerging countries.
The new funds will be used to advance the company's lead vaccine candidate for intestinal infections (Shigellosis), which can cause a major public health issue, into clinical development within the next 12 months. GlycoVaxyn also aims to reach key milestones in its Staphylococcus aureus, Group B meningococcal and Group A Streptococcus conjugate vaccine programs.
In conjunction with the financing,
"Under the leadership of CEO
GlycoVaxyn has built a broad portfolio of novel conjugate vaccines
against common severe bacterial infections based on its unique, proprietary
in-vivo glycosylation platform. With this platform, the company can develop
and produce immunogenic glycoproteins in a simplified biological process that
circumvents many of the difficulties involved in current methods. The lead
conjugate vaccines in development are directed against Shigella dysenteriae,
to prevent serious intestinal infections, and against hospital acquired
Staphylococcus aureus. GlycoVaxyn also has active programs against N.
meningitidis and Group A Streptococcus. GlycoVaxyn, a spin-out of the
SOURCE GlycoVaxyn AG